FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038613570> ?p ?o ?g. }

• W2038613570 abstract "Hydatidiform mole (HM), also called a molar pregnancy, is characterised by an overgrowth of foetal chorionic tissue within the uterus. HMs may be partial (PM) or complete (CM) depending on their gross appearance, histopathology and karyotype. PMs usually have a triploid karyotype, derived from maternal and paternal origins, whereas CMs are diploid and have paternal origins only. Most women with HM can be cured by evacuation of retained products of conception (ERPC) and their fertility preserved. However, in some women the growth persists and develops into gestational trophoblastic neoplasia (GTN), a malignant form of the disease that requires treatment with chemotherapy. CMs have a higher rate of malignant transformation than PMs. It may be possible to reduce the risk of GTN in women with HM by administering prophylactic chemotherapy (P-Chem). However, P-Chem given before or after evacuation of HM to prevent malignant sequelae remains controversial, as the risks and benefits of this practice are unclear.To systematically review the evidence for the effectiveness and safety of P-Chem to prevent GTN in women with a molar pregnancy.We performed electronic searches in the Cochrane Gynaecological Cancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 2, 2012), MEDLINE (1946 to February week 4, 2012) and EMBASE (1980 to week 9, 2012). The search strategy was developed using free text and medical subject headings (MESH). We handsearched reference lists of relevant literature to identify additional studies.We included randomised controlled trials (RCTs) of P-Chem for HM.Two review authors independently assessed studies for inclusion in the review and extracted data using a specifically designed data collection form. Meta-analyses were performed by pooling data from individual trials using RevMan 5.1 software.We included three RCTs with a combined total of 613 participants. One study compared prophylactic dactinomycin to no prophylaxis (60 participants); the other two studies compared prophylactic methotrexate to no prophylaxis (420 and 133 participants). All participants were diagnosed with CMs. We considered the latter two studies to be of poor methodological quality.P-Chem reduced the risk of GTN occurring in women following a CM (3 studies, 550 participants; RR 0.37; 95% confidence interval (CI) 0.24 to 0.57; I(2) = 0%; P < 0.00001), However, owing to the poor quality of two of the included studies, we performed sensitivity analyses excluding these two studies. This left only one small study of high-risk women to contribute data for this primary outcome (59 participants; RR 0.28; 95% CI 0.10 to 0.73; P = 0.01), therefore we consider this evidence to be of a low quality.The time to diagnosis was longer in the P-Chem group than the control group (2 studies, 33 participants; mean difference (MD) 28.72; 95% CI 13.19 to 44.24; P = 0.0003) and the P-Chem group required more courses to cure subsequent GTN (1 poor-quality study, 14 participants; MD 1.10; 95% CI 0.52 to 1.68; P = 0.0002). We consider this evidence to be of a low to very low quality for similar reasons to those listed above.There were insufficient data to perform meta-analyses for toxicity, overall survival, drug resistance and reproductive outcomes.P-Chem may reduce the risk of progression to GTN in women with CMs who are at a high risk of malignant transformation; however, current evidence in favour of P-Chem is limited by the poor methodological quality and small size of the included studies. As P-Chem may increase drug resistance, delay treatment of GTN and expose women unnecessarily to toxic side effects, this practice cannot currently be recommended." @default.
• W2038613570 created "2016-06-24" @default.
• W2038613570 creator A5000982380 @default.
• W2038613570 creator A5005584314 @default.
• W2038613570 creator A5011310207 @default.
• W2038613570 creator A5017211539 @default.
• W2038613570 creator A5043490198 @default.
• W2038613570 creator A5049500714 @default.
• W2038613570 creator A5055280881 @default.
• W2038613570 creator A5059271034 @default.
• W2038613570 creator A5084590554 @default.
• W2038613570 date "2017-09-11" @default.
• W2038613570 modified "2023-09-26" @default.
• W2038613570 title "Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia" @default.
• W2038613570 cites W1592247752 @default.
• W2038613570 cites W1595184853 @default.
• W2038613570 cites W161133495 @default.
• W2038613570 cites W1966605298 @default.
• W2038613570 cites W1971551124 @default.
• W2038613570 cites W1973061092 @default.
• W2038613570 cites W1974798745 @default.
• W2038613570 cites W1979617474 @default.
• W2038613570 cites W1985152936 @default.
• W2038613570 cites W2004185560 @default.
• W2038613570 cites W2010556689 @default.
• W2038613570 cites W2015474333 @default.
• W2038613570 cites W2018017698 @default.
• W2038613570 cites W2021198554 @default.
• W2038613570 cites W2028063483 @default.
• W2038613570 cites W2043297379 @default.
• W2038613570 cites W2047202741 @default.
• W2038613570 cites W2051629412 @default.
• W2038613570 cites W2054539541 @default.
• W2038613570 cites W2056932950 @default.
• W2038613570 cites W2058815242 @default.
• W2038613570 cites W2059357978 @default.
• W2038613570 cites W2106612113 @default.
• W2038613570 cites W2107328434 @default.
• W2038613570 cites W2111046733 @default.
• W2038613570 cites W2111866181 @default.
• W2038613570 cites W2113955549 @default.
• W2038613570 cites W2121389328 @default.
• W2038613570 cites W2125435699 @default.
• W2038613570 cites W2155486123 @default.
• W2038613570 cites W2204616367 @default.
• W2038613570 cites W2241667434 @default.
• W2038613570 cites W2265953486 @default.
• W2038613570 cites W2336313517 @default.
• W2038613570 cites W2886513860 @default.
• W2038613570 cites W4251913701 @default.
• W2038613570 cites W4252434684 @default.
• W2038613570 cites W4299741090 @default.
• W2038613570 doi "https://doi.org/10.1002/14651858.cd007289.pub3" @default.
• W2038613570 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6483742" @default.
• W2038613570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28892119" @default.
• W2038613570 hasPublicationYear "2017" @default.
• W2038613570 type Work @default.
• W2038613570 sameAs 2038613570 @default.
• W2038613570 citedByCount "25" @default.
• W2038613570 countsByYear W20386135702016 @default.
• W2038613570 countsByYear W20386135702017 @default.
• W2038613570 countsByYear W20386135702018 @default.
• W2038613570 countsByYear W20386135702019 @default.
• W2038613570 countsByYear W20386135702020 @default.
• W2038613570 countsByYear W20386135702021 @default.
• W2038613570 countsByYear W20386135702022 @default.
• W2038613570 countsByYear W20386135702023 @default.
• W2038613570 crossrefType "journal-article" @default.
• W2038613570 hasAuthorship W2038613570A5000982380 @default.
• W2038613570 hasAuthorship W2038613570A5005584314 @default.
• W2038613570 hasAuthorship W2038613570A5011310207 @default.
• W2038613570 hasAuthorship W2038613570A5017211539 @default.
• W2038613570 hasAuthorship W2038613570A5043490198 @default.
• W2038613570 hasAuthorship W2038613570A5049500714 @default.
• W2038613570 hasAuthorship W2038613570A5055280881 @default.
• W2038613570 hasAuthorship W2038613570A5059271034 @default.
• W2038613570 hasAuthorship W2038613570A5084590554 @default.
• W2038613570 hasBestOaLocation W20386135702 @default.
• W2038613570 hasConcept C126322002 @default.
• W2038613570 hasConcept C131872663 @default.
• W2038613570 hasConcept C172680121 @default.
• W2038613570 hasConcept C2776694085 @default.
• W2038613570 hasConcept C2776953305 @default.
• W2038613570 hasConcept C2778165768 @default.
• W2038613570 hasConcept C2778279030 @default.
• W2038613570 hasConcept C2778376644 @default.
• W2038613570 hasConcept C2778383414 @default.
• W2038613570 hasConcept C2779234561 @default.
• W2038613570 hasConcept C2780343435 @default.
• W2038613570 hasConcept C2908941940 @default.
• W2038613570 hasConcept C2909593222 @default.
• W2038613570 hasConcept C29456083 @default.
• W2038613570 hasConcept C46973012 @default.
• W2038613570 hasConcept C54355233 @default.
• W2038613570 hasConcept C71924100 @default.
• W2038613570 hasConcept C86803240 @default.
• W2038613570 hasConceptScore W2038613570C126322002 @default.
• W2038613570 hasConceptScore W2038613570C131872663 @default.
• W2038613570 hasConceptScore W2038613570C172680121 @default.
• W2038613570 hasConceptScore W2038613570C2776694085 @default.

• next